G1 Therapeutics Inc
NASDAQ:GTHX
G1 Therapeutics Inc
NASDAQ:GTHX
Price:
4.635 USD
5.34%
Updated:
May 3, 2024
G1 Therapeutics Inc
Cash from Investing Activities
|
G1 Therapeutics Inc
Cash from Investing Activities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Cash from Investing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
G1 Therapeutics Inc
NASDAQ:GTHX
|
Cash from Investing Activities
$2.8m
|
CAGR 3-Years
166%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Investing Activities
-$2B
|
CAGR 3-Years
62%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Investing Activities
-$2.3B
|
CAGR 3-Years
48%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-76%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Investing Activities
-$26.2B
|
CAGR 3-Years
-69%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-12%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Investing Activities
-$3.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-73%
|
CAGR 10-Years
-50%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Investing Activities
-$3.2B
|
CAGR 3-Years
-256%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-25%
|
See Also
What is G1 Therapeutics Inc's Cash from Investing Activities?
Cash from Investing Activities
2.8m
USD
2.8m
USD
Based on the financial report for Dec 31, 2023, G1 Therapeutics Inc's Cash from Investing Activities amounts to 2.8m USD.
What is G1 Therapeutics Inc's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 3Y
166%
166%
The average annual Cash from Investing Activities growth rates for G1 Therapeutics Inc have been 166% over the past three years .
You don't have any saved screeners yet
